Celldex Therapeutics’ (CLDX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report released on Wednesday,Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on CLDX. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. The Goldman Sachs Group started coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 5.7 %

CLDX stock opened at $26.40 on Wednesday. The company has a fifty day moving average price of $31.17 and a 200 day moving average price of $35.15. Celldex Therapeutics has a 12 month low of $22.93 and a 12 month high of $53.18.

Insider Buying and Selling at Celldex Therapeutics

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $26.82 per share, with a total value of $308,430.00. Following the purchase, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after acquiring an additional 1,167,659 shares during the last quarter. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 19.8% during the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock worth $153,215,000 after buying an additional 604,251 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after buying an additional 2,664,915 shares during the last quarter. Bellevue Group AG boosted its stake in Celldex Therapeutics by 3.4% in the 3rd quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after buying an additional 100,000 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after buying an additional 654,194 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.